Welcome to Novo Nordisk Science Hub

Are you a healthcare professional?

EASD 2026 28 September - 2 October 2026

UBT251, a triple hormone receptor agonist in adults with overweight or obesity: a multicenter, double-blind, placebo-controlled, randomized, phase 2 trial

Sorry! It looks like the page you are trying to access contains materials that are still under embargo. Please come back and check again later.
Keywords
Obesity
GLP-1 RA
Pre-clinical